Communiqués ABVC BioPharma, Inc.

Actions

ABVC

US00091F3047

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 07/06/2024			Varia. 5j.	Varia. 1 janv.
0,777 ^USD	-1,52 %		-2,15 %	-33,02 %

17/05	ABVC BioPharma, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
09/05	Abvc Biopharma, Inc. conclut un accord définitif avec Oncox Biopharma, Inc.	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Immunity Boosting Combination Therapy for Myelodysplastic Syndrome Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Eligible to Receive Aggregate Income of $13.75M and Royalties of up to $12.50M - Form 8-K	24/05	PU
Promising Combination Therapy for Tripple Negative Breast Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, Potential Income of $13.75M and Royalties of up to $12.50M - Form 8-K	15/05	PU
Combination Therapy Holds Promise for Pancreatic Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M	09/05	AQ
Combination Therapy Holds Promise for Pancreatic Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M - Form 8-K	09/05	PU
AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share	18/04	AQ
ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M	17/04	AQ
ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M	10/04	AQ
ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M	26/03	AQ
AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars	21/03	AQ
ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine	19/03	AQ
ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update	14/03	AQ
ABVC BioPharma : Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update - Form 8-K	14/03	PU
ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues	15/02	AQ
ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)	12/02	AQ
ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share	08/02	AQ
Bull Run 2024: Biopharma Healthcare Stocks Surge, Gaining Momentum: DYAI, ABVC, FWBI, VTAK, NEXI	08/01	AQ
ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees	03/01	AQ
ABVC BioPharma Shares Insights from Dr. Scott Irwin of Cedars-Sinai Medical Center over Depression in Cancer Patients Clinical Trials	05/12	AQ
ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M	16/11	AQ
ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results	15/11	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués ABVC BioPharma, Inc.

Actions

ABVC

US00091F3047

Communiqués

Filtres